GLPwatch
Antihyperglycemic medications for cardiovascular disease risk reduction.
Am J Manag Care · 2018
Last updated 2026-05-28Some diabetes medications are now tested to ensure they do not increase the risk of heart disease, while a few have been shown to actually lower heart-related risks, including death. These findings come from large clinical trials involving thousands of participants.
AI summary of the abstract below.
| Journal | Am J Manag Care, 2018 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
In recognition of the substantial prevalence of cardiovascular disease-related comorbidities among patients with diabetes and the potential for some agents to increase this risk, evaluation of cardiovascular outcomes is now a standard component of late-stage clinical trials involving antihyperglycemic agents. While most agents are evaluated in noninferiority trials to establish a lack of cardiovascular-related harm, a few agents have shown significant reductions in cardiovascular-related outcomes, including mortality.
Verbatim abstract via PubMed 30160394 ↗